Plain-English translation of NCT06773507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase 1) testing a new cancer medication called BC008-1A injection in people with advanced esophageal squamous cell carcinoma or non-small cell lung cancer. Researchers want to understand how safe the medication is, how the body processes it, and whether it can help slow or stop cancer growth. You would receive injections every three weeks at one of two dose levels (900mg or 1200mg).
Many patients with advanced esophageal and lung cancer do not respond well to standard treatments, or their cancer returns after treatment. This medication is being tested to see if it offers a new treatment option for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic every three weeks to receive an injection of the medication. Before starting, you'll have blood tests and imaging scans to confirm your cancer and check your organ function. You'll continue receiving injections every three weeks (called one 'cycle') until your cancer gets worse, you experience side effects you cannot tolerate, or your doctor decides it's no longer helping. Throughout the trial, you'll have regular blood tests and scans to monitor how your body is responding to the treatment.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~80 participants
Started
May 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianing Wang
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.